<DOC>
	<DOCNO>NCT02467426</DOCNO>
	<brief_summary>This observational study isolate thoracic perfusion subsequent hemofiltration low concentration cytotoxic drug locoregional therapeutic strategy malignant pleural mesothelioma .</brief_summary>
	<brief_title>Isolated Thoracic Perfusion ( ITP-F ) MPM</brief_title>
	<detailed_description>Treatment patient progressive malignant pleural mesothelioma ( MPM ) multimodal therapy therapeutic challenge . Survival patient low treatment option sparse . This observational study isolate thoracic perfusion subsequent hemofiltration locoregional therapeutic strategy situation . 23 pt . epithelioid MPM include phase II study inform consent . All patient progressive disease multiple therapy recommend BSC MDT . Following insertion venous arterial 21 ch . stop flow catheter via femoral access , inferior vena cava block beneath right atrium , arterial catheter block aorta diaphragm . The upper arm block pneumatic cuff . Chemotherapy give via arterial catheter . Chemotherapy consist 60mg/m2 cisplatinum 15mg/m2 mitoxantrone q 3 week progress . After administration chemotherapy , thoracic perfusion block stop-flow catheter maintain 15 minute . After de-blocking catheter , hemofiltration perform 45 min . 5l filtrate . The endpoint study overall survival.Secondary endpoint toxicity .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>History pretreated Malignant Pleural Mesothelioma , Progress Staging Drug abuse , distant metastasis , bone marrow function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Mesothelioma , malignant</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>